On November 9, 2026, the US Food and Drug Administration required manufacturers of all GLP-1 medications—including Novo Nordisk's Ozempic and Eli Lilly's Zepbound—to add safety warnings regarding a rare eye condition known as NAION. NAION causes reduced optic nerve blood flow and sudden vision loss. Agency meta-analysis revealed 6.4 NAION cases per 100,000 patient-years among GLP-1 users versus 3.8 in control groups. Novo Nordisk stated that data do not establish causation, while medical experts advise patients not to stop treatment without consulting physicians.
FDA warning label action
- ▪The Food and Drug Administration noted that a causal relationship between GLP-1 drugs and nonarteritic anterior ischemic optic neuropathy has not been definitively established
- ▪The FDA required all GLP-1 drug manufacturers to add a nonarteritic anterior ischemic optic neuropathy safety warning to drug labels
Evaluations of GLP-1 NAION risk
- ▪The Food and Drug Administration began evaluating nonarteritic anterior ischemic optic neuropathy risks after a 2024 observational study linked semaglutide prescriptions to the eye condition
- ▪Cases of nonarteritic anterior ischemic optic neuropathy have been reported across all currently marketed GLP-1 medications, including semaglutide and tirzepatide products
- ▪A Food and Drug Administration Sentinel network study found GLP-1 users had a higher NAION risk compared to DPP-4 inhibitor users (hazard ratio 1.43), but not SGLT2 inhibitor users (hazard ratio 1.19)
- ▪A Food and Drug Administration meta-analysis of 126 clinical trials involving 134,253 patients found 6.4 NAION cases per 100,000 person-years among GLP-1 users compared to 3.8 among control groups
Patient guidance on GLP-1 use
- ▪The American Academy of Ophthalmology advised patients taking GLP-1 drugs not to discontinue their medication without consulting a doctor despite the small potential risk of NAION
- ▪The Food and Drug Administration advised patients using GLP-1 medications to report sudden acute, painless decreased vision or visual field deficits immediately
Novo Nordisk response
- ▪Novo Nordisk stated that available clinical data do not establish a cause-and-effect relationship between GLP-1 medications and nonarteritic anterior ischemic optic neuropathy
- ▪Novo Nordisk stated that it remains confident in the benefit-risk profile of its GLP-1 medicines, including Ozempic and Wegovy, and continues to monitor their safety
Citi analyst projections
- ▪Citi analysts projected that the health benefits of GLP-1 drugs will maintain a favorable benefit-risk profile despite temporary patient and investor concerns
- ▪Citi analysts projected that the Food and Drug Administration's NAION warning label action will likely attract public attention but have a limited long-term impact on GLP-1 drug prescribing and uptake
Overview of NAION
- ▪Nonarteritic anterior ischemic optic neuropathy is a rare eye condition caused by reduced blood flow to the optic nerve that can lead to sudden, permanent vision loss or blindness
- ▪The American Academy of Ophthalmology stated that nonarteritic anterior ischemic optic neuropathy is the most common cause of acute optic nerve injury in people over 50 years old
Story comments
Loading comments…